Estimated global and regional economic burden of genital herpes simplex virus infection among 15–49 year-olds in 2016
2024

Economic Burden of Genital Herpes Infections

publication Evidence: high

Author Information

Author(s): Chaiyakunapruk Nathorn, Lee Shaun Wen Huey, Kulchaitanaroaj Puttarin, Rayanakorn Ajaree, Lee Haeseon, Looker Katharine Jane, Hutubessy Raymond, Gottlieb Sami L.

Primary Institution: Department of Pharmacotherapy, College of Pharmacy, University of Utah

Hypothesis

This study aims to estimate the global economic impact of genital HSV-2 and HSV-1 infection.

Conclusion

The global costs of genital HSV infection and its consequences are substantial, highlighting the need for HSV prevention interventions.

Supporting Evidence

  • The estimated economic burden of genital HSV infection globally was I$35.3 billion in 2016.
  • HSV-2 accounted for I$31.2 billion of the total economic burden.
  • High- and upper-middle-income countries bore 76.6% of the economic burden.

Takeaway

Genital herpes is very expensive for the world because it causes a lot of health problems and costs money for treatment. Making a vaccine could help save money and lives.

Methodology

The economic burden was calculated using a societal perspective, incorporating healthcare resource utilization and costs from a literature review and expert interviews.

Potential Biases

The estimates relied on expert opinions and assumptions about healthcare resource utilization, which may introduce bias.

Limitations

The study did not include costs associated with non-genital HSV outcomes and was limited by the availability of healthcare resource utilization data in some regions.

Participant Demographics

The study focused on individuals aged 15-49 years globally.

Digital Object Identifier (DOI)

10.1186/s44263-024-00053-6

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication